Literature DB >> 33074330

Differences in Influenza-Specific CD4 T-Cell Mediated Immunity Following Acute Infection Versus Inactivated Vaccination in Children.

Ian Shannon1, Chantelle L White2, Hongmei Yang3, Jennifer L Nayak1.   

Abstract

BACKGROUND: Early childhood influenza infections imprint influenza-specific immune memory, with most studies evaluating antibody specificity. In this study, we examined how infection versus inactivated influenza vaccination (IIV) establish pediatric CD4 T-cell mediated immunity to influenza and whether this poises the immune system to respond differently to IIV the following year.
METHODS: We tracked influenza-specific CD4 T-cell responses in 16 H3N2 infected and 28 IIV immunized children following both initial exposure and after cohorts were revaccinated with IIV the following fall. PBMCs were stimulated with peptide pools encompassing the translated regions of the H3 HA and NP proteins and were then stained to assess CD4 T-cell specificity and function.
RESULTS: Compared to IIV, infection primed a greater magnitude CD4 T-cell response specific for the infecting HA and NP proteins, with more robust NP-specific immunity persisting through year 2. Post infection, CD4 T cells preferentially produced combinations of cytokines that included interferon-γ. Interestingly, age-specific patterns in CD4 T-cell reactivity demonstrated the impact of multiple influenza exposures over time.
CONCLUSIONS: These data indicate that infection and vaccination differentially prime influenza-specific CD4 T-cell responses in early childhood, with these differences contributing to the lasting immunologic imprinting established following early influenza infection. CLINICAL TRIALS REGISTRATION: NCT02559505.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  CD4 T cells; cellular immune response; influenza immunity; pediatrics

Mesh:

Substances:

Year:  2021        PMID: 33074330      PMCID: PMC8205642          DOI: 10.1093/infdis/jiaa664

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  35 in total

1.  Intracellular cytokine optimization and standard operating procedure.

Authors:  Laurie Lamoreaux; Mario Roederer; Richard Koup
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

2.  Immune response to split-product influenza vaccine in preterm and full-term young children.

Authors:  J R Groothuis; M J Levin; M V Lehr; J A Weston; A R Hayward
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

3.  Broad Hemagglutinin-Specific Memory B Cell Expansion by Seasonal Influenza Virus Infection Reflects Early-Life Imprinting and Adaptation to the Infecting Virus.

Authors:  Brenda L Tesini; Preshetha Kanagaiah; Jiong Wang; Megan Hahn; Jessica L Halliley; Francisco A Chaves; Phuong Q T Nguyen; Aitor Nogales; Marta L DeDiego; Christopher S Anderson; Ali H Ellebedy; Shirin Strohmeier; Florian Krammer; Hongmei Yang; Sanjukta Bandyopadhyay; Rafi Ahmed; John J Treanor; Luis Martinez-Sobrido; Hana Golding; Surender Khurana; Martin S Zand; David J Topham; Mark Y Sangster
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

4.  Seasonal Influenza Vaccination of Children Induces Humoral and Cell-Mediated Immunity Beyond the Current Season: Cross-reactivity With Past and Future Strains.

Authors:  Adrian J Reber; Jin Hyang Kim; Laura A Coleman; Sarah M Spencer; Jessie R Chung; Jufu Chen; Paul Gargiullo; Maria E Sundaram; Edward A Belongia; David K Shay; Jacqueline M Katz; Suryaprakash Sambhara
Journal:  J Infect Dis       Date:  2016-08-28       Impact factor: 5.226

5.  Selective and quantitative detection of influenza virus proteins in commercial vaccines using two-dimensional high-performance liquid chromatography and fluorescence detection.

Authors:  Virginia García-Cañas; Barry Lorbetskie; Diane Bertrand; Terry D Cyr; Michel Girard
Journal:  Anal Chem       Date:  2007-03-16       Impact factor: 6.986

6.  In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses.

Authors:  Mary Dawn T Co; Laura Orphin; John Cruz; Pamela Pazoles; Karin M Green; James Potts; Anita M Leporati; Jenny Aurielle B Babon; James E Evans; Francis A Ennis; Masanori Terajima
Journal:  Vaccine       Date:  2008-10-31       Impact factor: 3.641

7.  Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis.

Authors:  Matthew S Miller; Thomas J Gardner; Florian Krammer; Lauren C Aguado; Domenico Tortorella; Christopher F Basler; Peter Palese
Journal:  Sci Transl Med       Date:  2013-08-14       Impact factor: 17.956

8.  Childhood immune imprinting to influenza A shapes birth year-specific risk during seasonal H1N1 and H3N2 epidemics.

Authors:  Katelyn M Gostic; Rebecca Bridge; Shane Brady; Cécile Viboud; Michael Worobey; James O Lloyd-Smith
Journal:  PLoS Pathog       Date:  2019-12-19       Impact factor: 6.823

Review 9.  Vaccines for preventing influenza in healthy children.

Authors:  Tom Jefferson; Alessandro Rivetti; Carlo Di Pietrantonj; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2018-02-01

10.  Baseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines.

Authors:  Xiao-Song He; Tyson H Holmes; Sanae Sasaki; Maria C Jaimes; George W Kemble; Cornelia L Dekker; Ann M Arvin; Harry B Greenberg
Journal:  PLoS One       Date:  2008-07-02       Impact factor: 3.240

View more
  1 in total

1.  Opposing Effects of Prior Infection versus Prior Vaccination on Vaccine Immunogenicity against Influenza A(H3N2) Viruses.

Authors:  Annette Fox; Louise Carolan; Vivian Leung; Hoang Vu Mai Phuong; Arseniy Khvorov; Maria Auladell; Yeu-Yang Tseng; Pham Quang Thai; Ian Barr; Kanta Subbarao; Le Thi Quynh Mai; H Rogier van Doorn; Sheena G Sullivan
Journal:  Viruses       Date:  2022-02-25       Impact factor: 5.048

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.